Rastislav Bahleda
Université Paris-Saclay(FR)Institut Gustave Roussy(FR)
Publications by Year
Research Areas
Fibroblast Growth Factor Research, Bladder and Urothelial Cancer Treatments, Sarcoma Diagnosis and Treatment, Urinary and Genital Oncology Studies, Gastrointestinal Tumor Research and Treatment
Most-Cited Works
- → Immune-related adverse events with immune checkpoint blockade: a comprehensive review(2016)2,094 cited
- → High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial(2017)760 cited
- → Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors(2015)380 cited
- → Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study(2021)239 cited
- → Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors(2019)238 cited
- → Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)(2017)218 cited
- → Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors(2013)198 cited
- → Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial(2019)193 cited
- → Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors(2020)147 cited
- → A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors(2016)141 cited